WikiMD logo

COVID-19 portal | Vitamin D | CDC | Vaccine | Ketogenic diet

WikiMD is the world's largest medical encyclopedia with
327,162 articles, 3,625,955 edits, & 32,848,624 views

Let food be thy medicine, and medicine be thy food - Hippocrates


From WikiMD
Jump to navigation Jump to search

Information about Ribociclib

Ribociclib is a unique cyclin-dependent kinase inhibitor that is used in combination with aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer.

Liver safety of Ribociclib

Ribociclib is associated with a moderate rate of serum aminotransferase elevations during therapy, and to clinically apparent liver injury in a proportion of these.

Mechanism of action of Ribociclib

Ribociclib (rye" boe sye' klib) is an orally available, small molecule inhibitor of cyclin-dependent kinases 4 and 6 that is used in combination with aromatase inhibitors in the therapy of postmenopausal women with metastatic breast cancer that is positive for the estrogen hormone receptor (ER+), but negative for human epidermal growth factor receptor 2 (HER2-). The cyclin kinases 4 and 6 regulate the cellular transition from the G1 to the S phase of the cell cycle acting through the retinoblastoma protein (Rb) pathway. Inhibition of this transition blocks the progression of the cell cycle and results in growth arrest in rapidly dividing cells. Components of this pathway are often mutated or overexpressed in cancer cells. In several clinical trials, the addition of ribociclib to letrozole (aromatase inhibitor) therapy of advanced or metastatic breast cancer (ER+, HER2-) in postmenopausal women was associated with a prolongation of disease-free but not overall survival.

FDA approval information for Ribociclib

Ribociclib received accelerated approval for use in the United States in 2017. Ribociclib is under investigation as therapy of several solid tumors and lymphomas, but the initial indications were limited to advanced or metastatic ER+, HER2- breast cancer in postmenopausal women given in combination with an aromatase inhibitor.

Dosage and administration for Ribociclib

Ribociclib is available in tablets of 200 mg under the brand name Kisqali, and the initial recommended dose is 600 mg once daily in 21 day cycles every 28 days indefinitely or until there is disease progression.

Side effects of Ribociclib

Common side effects include neutropenia, fatigue, nausea, diarrhea, anorexia, thrombocytopenia, headache and back pain. Less common, but potentially severe adverse reactions include prolongation of the QTc interval, severe neutropenia, fever and infections, and embryo-fetal toxicity.

Cost and Coupons - Ribociclib

Reviews for Ribociclib

The article on Ribociclib is a stub. YOU can help Wikimd by expanding it!

Medication resources

Learn more


WikiMD Resources - Ribociclib

Help WikiMD:Join WikiMD as an an editor and help improve the page Ribociclib or others.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="">Ribociclib</a>

  • Individual results may vary for weight loss from our sponsors.